Engineered immune cells target HPV cancers in new trial
NCT ID NCT05686226
Summary
This study is testing a new gene therapy for people with advanced cancers caused by HPV. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack HPV-infected cancer cells, and then infuse them back into the patient. The goal is to see if this personalized cell therapy can shrink tumors in cancers that have spread or come back after standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
RWJBarnabas Health - Robert Wood Johnson University Hospital
RECRUITINGNew Brunswick, New Jersey, 08901, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rutgers Cancer Institute
RECRUITINGNew Brunswick, New Jersey, 08901, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.